



Resource impact statement

Resource impact

Published: 9 March 2022

www.nice.org.uk

No significant resource impact is anticipated

[NICE has recommended pegcetacoplan](#), within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor. It is recommended only if the company provides pegcetacoplan according to the commercial arrangement (see [section 2 of guidance](#)).

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the technology is a further treatment option and the overall cost of treatment for this patient group is unlikely to change significantly with the introduction of pegcetacoplan.

Pegcetacoplan has a discount that is commercial in confidence. For enquiries about the patient access scheme contact mail.uk@sobi.com.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.